OR13C2

Across TCGA pan-cancer cohorts, OR13C2 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated OR13C2 data layer compared with 2 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher OR13C2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR13C2 expression acts as an unfavorable survival marker, although some lineages such as SARC and THYM show a favorable association.

BLCA, ESCA, and SARC are the cancer types where OR13C2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	IV	0.046	0.606	<.001	72	view →
ESCA	OS	Tertile	IV	0.095	0.512	.008	36	view →
SARC	OS	Tertile	All	0.944	0.430	.005	24	view →
LUAD	DFS	Tertile	IV	0.333	0.671	.048	18	view →
HNSC	DFS	Tertile	IV	0.190	0.584	.035	18	view →
LAML	DFS	Median	All	0.432	0.709	.004	12	view →
SKCM	OS	Tertile	IV	0.226	0.613	.034	9	view →
THYM	DFS	Median	III,IV	1.000	0.498	.017	9	view →
ACC	DFS	Tertile	III,IV	0.077	0.469	.027	9	view →
BRCA	OS	Tertile	III,IV	1.000	0.516	.045	6	view →
PAAD	DFS	Tertile	All	0.583	0.244	.023	6	view →
PCPG	OS	Quartile	All	0.612	0.982	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

OR13C2–BLCA (OS)

Open the BLCA breakdown →